As hard as it might seem to justify green-thumbing a company that sounds like a sneeze, I'm going to give it a shot anyway.In 2006 Achillion (bless you) stock maxed out at 20 on the strength of a partnership with Gilead on hepatitis C antiviral… More
Achillion survived a 50M dilutive financing in August to rise significantly after the initiation of the phase II trial of ACH-1625. These events mean that Achillion will end the year with a comfortable cash cushion but also a bloated market cap which… More